A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

700

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Saruparib
DRUG: Placebo
DRUG: Abiraterone + Prednisolone/Prednisone
DRUG: Androgen Deprivation Therapy (ADT)

Sponsor

AstraZeneca

Collaborators

[object Object]